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Strengths and limitations of this study
 ► This systematic overview included the comprehen-
sive literature search of important complementa-
ry and alternative medicine topics defined by the 
Cochrane Collaboration.
 ► The inclusion criteria were restricted to meta-anal-
yses of randomised controlled clinical trials (RCTs) 
of patients with a clinical diagnosis of depression.
 ► The quality of evidence from meta-analyses was 
assessed according to Grades of Recommendation, 
Assessment, Development, and Evaluation.
 ► There is a possible lack of evidence of newer RCTs, 
which have not been analysed by the included 
meta-analyses.
AbStrACt
Objectives As clinical practice guidelines vary widely 
in their search strategies and recommendations of 
complementary and alternative medicine (CAM) for 
depression, this overview aimed at systematically 
summarising the level 1 evidence on CAM for patients with 
a clinical diagnosis of depression.
Methods PubMed, PsycInfo and Central were searched 
for meta-analyses of randomised controlled clinical trials 
(RCTs) until 30 June 2018. Outcomes included depression 
severity, response, remission, relapse and adverse events. 
The quality of evidence was assessed according to 
Grades of Recommendation, Assessment, Development, 
and Evaluation (GRADE) considering the methodological 
quality of the RCTs and meta-analyses, inconsistency, 
indirectness, imprecision of the evidence and the potential 
risk of publication bias.
results The literature search revealed 26 meta-analyses 
conducted between 2002 and 2018 on 1–49 RCTs in 
major, minor and seasonal depression. In patients with 
mild to moderate major depression, moderate quality 
evidence suggested the efficacy of St. John’s wort towards 
placebo and its comparative effectiveness towards 
standard antidepressants for the treatment for depression 
severity and response rates, while St. John’s wort 
caused significant less adverse events. In patients with 
recurrent major depression, moderate quality evidence 
showed that mindfulness-based cognitive therapy was 
superior to standard antidepressant drug treatment for the 
prevention of depression relapse. Other CAM evidence was 
considered as having low or very low quality.
Conclusions The effects of all but two CAM treatments 
found in studies on clinical depressed patients based on 
low to very low quality of evidence. The evidence has to 
be downgraded mostly due to avoidable methodological 
flaws of both the original RCTs and meta-analyses not 
following the Consolidated Standards of Reporting Trials 
and Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses guidelines. Further research is needed.
IntrOduCtIOn
Depression is one of the most prevalent 
psychiatric disorders, with about 25% of 
women and 12% of men suffering from at 
least one depressive episode during their life-
time.1–3 According to the criteria for diagnosis 
recommended by the American Psychiatric 
Association (APA), depressive disorders can 
be distinguished by their degree of severity or 
duration and are also characterised by a high 
comorbidity and an increase of psychological 
strain for the affected person.4 It is evident 
that a strong comorbid connection to several 
chronic conditions like addictions,5 neurode-
generative diseases6 7 or different psychiatric 
diseases8–11 exists. This leads depressive disor-
ders as one of the leading causes of disability 
worldwide.12
The most commonly used treatments 
for depression are antidepressants, psycho-
therapy or a combination of drugs and 
psychotherapy. While both treatment strat-
egies (alone and in combination) have 
been shown to be effective,13–15 more recent 
meta-analyses also found high dropout and 
low remission rates16–21 as well as clinically 
significant differences between antidepres-
sant drugs and placebos only for patients at 
the upper end of the very severely depressed 
category.22 This may lead patients to search 
for alternatives. Increasing mainstream use 
of complementary and alternative medicine 
(CAM) support this trend, particularly for 
different physical conditions with comorbid 
affective disorders.23–27 The NIH defines CAM 
as therapeutic approaches that are usually not 
included in conventional Western medicine 
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with conventional care are considered as complementary, 
those used instead of conventional care as alternative 
practices. Types of CAM approaches include natural prod-
ucts, such as herbs and dietary supplements (vitamins, 
minerals and probiotics) and mind and body practices, 
such as yoga, chiropractic and osteopathic manipulation, 
meditation, relaxation, acupuncture, tai chi, qi gong 
and hypnotherapy. Practices of traditional healers from 
Europe (naturopathy and homeopathy), Asia (Ayurveda 
and traditional Chinese medicine) and other continents 
are also classified as CAM.28 While some complementary 
therapies have become a promising adjunct in the stan-
dard treatment of depression,29 30 others are known for 
their possible side effects or interactions with standard 
drugs.30 Recent clinical practice guidelines, in addition, 
vary widely in their search strategies and resulting recom-
mendations for CAM treatments. While the American 
College of Physicians (ACP),31 the American Psychiatric 
Association (APA)32 and the Canadian Network for Mood 
and Anxiety Treatments (CANMAT) guideline33 provide 
a more comprehensive overview and critical appraisal of 
CAM treatments, the Deutsche Gesellschaft für Psychi-
atrie und Psychotherapie, Psychosomatik und Nerven-
heilkunde (DGPPN),34 the National Institute for Health 
and Care Excellence (NICE),35 and the World Federation 
of Societies of Biological Psychiatry (WFSBP)36 guide-
lines mainly focus on St. John’s Wort and light therapy. 
Possible effects and risks of further CAM therapies are 
not discussed. Thus, the purpose of this overview is to 
provide a comprehensive search strategy of relevant CAM 
terms and systematically summarise the existing level 
1 evidence for clinical depression as a basis for further 
guideline recommendations on the efficacy, effectiveness 
and safety of CAM therapies.
MethOdS
This systematic overview of reviews was conducted in accor-
dance with the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) guidelines37 38 and 
the recommendations of the Cochrane Collaboration.39 
The protocol was not prospectively registered.
Patient and public involvement
For this overview of reviews, patients or public were not 
involved.
Inclusion and exclusion criteria
 ► Types of studies: to be eligible, articles had to be 
systematic reviews with meta-analyses of randomised 
controlled trials (RCTs) published in peer-reviewed 
journals. Conference abstracts or unpublished work 
were excluded as well as reviews summarising evidence 
narratively. In cases of including same or similar orig-
inal studies, only the review with the most recent, most 
comprehensive search was included. When systematic 
reviews reported results of RCTs as well as of designs 
of lower evidence levels, they were considered only 
if separate meta-analyses for the included RCTs were 
performed.
 ► Types of participants: only reviews of patients with 
a diagnosis of major depression or dysthymia were 
eligible as well as reviews including patients/general 
population samples with mild depressive symp-
toms above a clinical cut-off or seasonal patterns. 
In contrast, reviews studying depressive symptoms 
within specific subpopulations of substance-induced 
or demented patients, secondary depression due to 
another medical condition (eg, poststroke, cancer 
or pain patients), bipolar disorders, or females with 
premenstrual dysphoric disorder or postpartum 
depression were excluded. Further restrictions 
regarding the diagnostic criteria or procedures, 
regarding age, gender, duration of the condition or 
symptom intensity were not applied.
 ► Types of interventions: reviews investigating the 
effectiveness and/or safety of a single, adjunctive or 
combined CAM treatment were included. For the 
classification of CAM treatments the definition of 
the US National Institutes of Health40 was followed. 
CAM interventions have to be compared against treat-
ment as usual (TAU)/waiting list, placebo/sham or 
standard medical care.
 ► Types of outcomes: reviews were eligible if they 
assessed at least one measure of effectiveness such as 
severity of depressive symptoms, response rate (gener-
ally defined as a 50% decrease in depression scores 
after a period of up to 12 weeks of treatment),31 remis-
sion rate (generally defined as a period of up to 12 
weeks during which a patient is asymptomatic or has 
only few symptoms to a very mild degree),41 relapse 
rates and/or a measure of safety such as number of 
adverse events (AEs), drug interactions or numbers 
needed to harm for study withdrawal due to side 
effects.
Search strategy
Electronic literature was systematically searched via 
PubMed, PsycInfo and Central from their inception 
to 31 January 2018, without restrictions regarding 
time or language. Search terms for CAM treatments 
were selected in accordance with Cochrane recom-
mendations (table 1).42 Additional manual search 
included reference lists of previously published 
reviews14 29 30 43 and clinical practice guidelines.31–36 
Using PubMed Informer,44 the search was updated until 
30 June 2018.
Study selection process
To assess eligibility, articles were selected by screening 
titles and abstracts independently by two authors (HH 
and DA). Any abstract considered potentially eligible by 
at least one author was read in full to decide on its eligi-
bility. Disagreements were rechecked with a third author 
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Table 1 Electronic search strategy for PubMed
#1 (Depression OR Depressive Disorder, Major OR Depressive Disorder, Treatment-Resistant OR Dysthymic Disorder 
OR Seasonal Affective Disorder)(mh)
#2 (depress* OR dysthym* or “seasonal affective” OR “affective disorder” OR “affective disorders“ OR “mood 
disorder” OR “mood disorders”)(tiab)
#3 (Systematic review OR Meta-analysis)(pt) OR (Systematic* OR Meta-analy*)(tiab)
#4 (Acupressure OR Acupuncture OR acid OR Alexander Technique OR alternative OR Aromatherapy OR Aroma 
Therapy OR Art Therap* OR ayurved* OR Balneotherapy OR Balneo Therapy OR bee OR Biofeedback OR 
Bio Feedback OR bright light OR Chelation Therapy OR Chinese Traditional Medicine OR Chiropractic OR 
Chronotherapy OR Color Therapy OR complementary OR craniosacral OR cupping OR Curcumin OR Dance 
Therapy OR diet OR Distant Healing OR Electroacupuncture OR Feldenkrais OR folic acid OR Folate OR Healing 
Touch OR herbal OR Herbs OR Homeopath* OR Honey OR Hydrotherapy OR hyperbaric oxygenation OR 
Hypericum perforatum OR Hyperthermia OR Hypnosis OR Imagery OR Inositol OR Kampo OR Light Therapy 
OR Magnesium OR Massage OR MBSR OR MBCT OR Meditation OR Mindfulness OR Morita Therapy OR 
Moxibustion OR Mediterranean OR Music Therap* OR Naturopathy OR Neural Therapy OR Omega-3 OR 
Osteopath* OR Ozone Therapy OR Phototherapy OR Pollen OR Prayer OR prebiotic* OR probiotic* OR Propolis 
OR Qi Gong OR Reflexology OR Reiki OR Relaxation OR Rolfing OR Royal Jelly OR S-adenosyl-L-methionine OR 
Saffron OR Shamanism OR Snoezelen OR Speleotherapy OR Spinal Manipulation OR Spiritual OR St John's Wort 
OR Supplements OR Tai Chi OR TCM OR Therapeutic Touch OR Traditional Chinese Medicine OR Tryptophan OR 
Tui na OR Turmeric OR vegan OR vegetarian OR venom OR Vitamin OR Yoga OR zinc)(tiab)
#5 (Acupressure OR Acupuncture OR Acupuncture Therapy OR Acids OR Aromatherapy OR Art Therapy OR 
Balneology OR Biofeedback, Psychology OR Chelation Therapy OR Chiropractic OR Chronotherapy OR 
Color Therapy OR Complementary Therapies OR Crocus OR Curcuma OR Dance Therapy OR Diet OR 
Electroacupuncture OR Fatty Acids, Omega-3 OR Folic Acid OR Homeopathy OR Honey OR Hydrotherapy OR 
Hypericum OR Hyperthermia, Induced OR Hypnosis OR Imagery OR Inositol OR Magnesium OR Manipulation, 
Spinal OR Massage OR Medicine, Ayurvedic OR Medicine, Chinese Traditional OR Medicine, Kampo OR 
Meditation OR Mind-Body Therapies OR Mindfulness OR Moxibustion OR Naturopathy OR Ozone OR 
Phototherapy OR Plants, Medicinal OR Pollen OR Prebiotics OR Probiotics OR Propolis OR Qigong OR Relaxation 
OR Shamanism OR Speleotherapy OR Spiritual Therapies OR Supplements, Dietary OR Tai Ji OR Therapeutic 
Touch OR Tryptophan OR Venoms OR Vitamins OR Yoga OR Zinc)(mh)
#6 (#1 OR #2) AND #3 AND (#4 OR #5)
data extraction and quality assessment
Two authors (HH and DA) independently extracted data 
on the characteristics of the reviews including the type of 
the intervention, the year of publication, the number and 
quality of the original RCTs, the total number and age 
of the participants and effectiveness and safety outcomes. 
The quality of the included reviews was assessed using the 
Assessment of the Methodological Quality of Systematic 
Reviews (AMSTAR) tool.45 The AMSTAR tool consists of 
11 items asking about important methodological quality 
criteria of systematic reviews such as: a published a priori 
design, duplicate study selection and data extraction, a 
comprehensive literature search including grey litera-
ture, a list of included and excluded studies, summarised 
characteristics and quality assessment of included studies, 
assessment of publication bias, appropriate method of 
data syntheses and deducing conclusions and a conflict 
of interests statement. AMSTAR has shown good 
construct validity and inter-rater reliability. The Intra-
class Correlation Coefficient (ICC) of the total AMSTAR 
score of 11 points was reported as 0.84.46 For this anal-
ysis, the two authors (HH and DA) who independently 
assessed AMSTAR reached an ICC of 0.96. Disagreements 
regarding content or quality of the reviews were rechecked 
with a third author (HC) and resolved by agreement.
data synthesis
Results were pooled qualitatively by type of the interven-
tion. Outcomes had to be calculated as standard mean 
differences (SMDs), risk ratios (RRs), HRs or ORs. If 
meta-analyses displayed mean differences, SMDs were 
calculated using Review Manager Software (RevMan, 
V.5.3, The Nordic Cochrane Centre, Copenhagen, 
Denmark) for better comparability of the results. RevMan 
was also used to exclude SMDs/RRs/HRs/ORs of selec-
tive RCTs that did not fulfil eligibility criteria of this over-
view. Effect sizes were classified according to Cohen as 
SMDs of 0.2–0.49=small effect, SMDs of 0.5–0.79=medium 
effect and SMDs of >0.8=large effect (absolute values)47 
with higher reduction of/improvement in depression 
scores represented by more negative SMDs or RRs/HRs/
ORs less than 1. According to the NICE guideline, an 
SMD of ≥0.5 or ≤−0.5, respectively, was considered as a 
clinically relevant reduction of depression severity.48 
Statistical heterogeneity between studies was assessed 
by the χ2 test with a p value of ≤0.10 indicating signifi-
cant heterogeneity. The magnitude of heterogeneity 
was categorised by the I² statistic with I² of 0%–24%=no 
heterogeneity, I² of 25%–49%=moderate heterogeneity, 
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Figure 1 Study flow diagram. CAM, complementary and alternative medicine; RCTs, randomised controlled clinical trials.
Quality of evidence
The quality of evidence was assessed according to the 
Grades of Recommendation, Assessment, Development, 
and Evaluation (GRADE) approach49 individually by two 
authors (HH and DA). Disagreements were rechecked 
with a third author (HC) until consensus was achieved. 
For each outcome, the evidence can be graded as high, 
moderate, low or very low. Evidence from RCTs is initially 
assessed as high, but can be downgraded by one level for 
serious or two levels for very serious limitations of the 
study quality (of both RCTs and meta-analyses), inconsis-
tency of the results, indirectness of the evidence, impreci-
sion of the results and a potential risk of publication bias 
(as assessed by the included meta-analyses).49
reSultS
Study selection
A total of 3582 potentially eligible articles were identified 
by electronic database search. One additional review was 
retrieved from manual search,50 one from the updated 
search until June 2018.51 After removing duplicates, 
2639 articles were excluded by screening of titles and 
abstracts. The remaining 117 articles were read in full, of 
which further 91 reviews had to be excluded (figure 1). 
Reasons for exclusion comprised 55 reviews where newer 
and/or more comprehensive reviews on higher quality 
evidence were available.50–104 Further 15 reviews have to 
be excluded as they systematically summarised evidence 
but did not perform a meta-analysis mostly due to clinical 
heterogeneity or a limited number of available RCTs.105–119 
Eight reviews were excluded as they included mixed 
depressive samples of bipolar or postpartum cases and 
did not provide (data for) subgroup analyses for patients 
with the defined depression criteria.120–127 Another six 
reviews contained community samples with non-clin-
ical depression or physically ill patients with comorbid 
depressive symptoms but displayed no data for patients 
with a primary diagnosis of depression.128–133 Four reviews 
performed meta-analyses on both RCTs and non-RCTs 
and did not perform subgroup analyses or extracted 
sufficient data for post hoc analyses.134–137 Three of the 
reviews analysed standard instead of complementary ther-
apies and were therefore excluded. Finally, 26 meta-anal-
yses could be included and reviewed.138–163
review characteristics and quality
Characteristics and quality appraisal of the included 
meta-analyses are summarised in the online supplemen-
tary table 1. Meta-analyses were conducted between 2002 
and 2018 and included between 1 and 49 RCTs on 40–7104 
adult patients. Meta-analyses on children and adolescents 
were not available or did not meet inclusion criteria. 
Samples mostly consisted of patients suffering from major 
depressive disorder140–143 145–151 154 156 157 159 160 but also 
included patients with mixed diagnoses of non-seasonal 
depression,138 153 162 163 patients with a diagnosis of seasonal 
depression152 and patients with mild to severe symptoms of 
depression above a clinical cut-off.139 141 144 145 151 155 157 158 All 
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Figure 2 Quality of evidence for depression severity. ADM, antidepressant medication; CBT, cognitive–behavioural therapy; 
I2, heterogeneity; MBCT, mindfulness-based cognitive therapy; MBSR, mindfulness-based stress reduction; n.c., not calculable 
because of only one included randomised controlled clinical trials; n.r., not reported; SAMe, S-adenosyl methionine; TAU, 
treatment as usual.
on common standardised questionnaires or diagnostic 
interviews. Effects were analysed mostly up to 12 weeks of 
treatment (short term), except for four meta-analyses that 
included RCTs with effects reported up to 16, 24 or 32 
weeks138 142 143 151 160 and further three meta-analyses with 
long-term analyses equal to or greater than 1 year.149 157 163 
The AMSTAR total scores of the included meta-analyses 
ranged between 4 and 11 points with a median quality of 
7 points. The individual AMSTAR ratings are reported in 




A high-quality Cochrane review meta-analysed 49 RCTs in 
major depressed adults as well as those with clinically rele-
vant symptoms of depression for manual acupuncture.138 
For depression severity, significant effect sizes were found 
in comparisons with TAU and as in adjunction to stan-
dard antidepressants, while acupuncture showed similar 
effects to invasive sham acupuncture and standard anti-
depressants (figure 2). The analyses of remission rates 
did not reveal superiority of acupuncture in the compar-
isons with TAU, invasive sham, standard antidepressants 
or in adjunction to standard antidepressants (figure 3). 
AEs reported in the acupuncture groups were signifi-
cantly lower than in patients treated with antidepressant 
drugs. However, most meta-analyses showed significant 
heterogeneity, a lack of RCTs with low risk of bias and a 
possibly serious risk of publication bias. Thus, the quality 
of evidence had to be downgraded to low and very low.
Electroacupuncture
For electroacupuncture, the same Cochrane review138 
revealed very low quality of evidence for the comparisons 
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Figure 3 Quality of evidence for depression remission rates. ADM, antidepressant medication; I2, heterogeneity; RR, risk ratio; 
TAU, treatment as usual.
Figure 4 Quality of evidence for depression response rates. ADM, antidepressant medication; I2, heterogeneity; n.c., not 
calculable because of only one included randomised controlled clinical trials; RR, risk ratio.
(figure 2) and remission (figure 3), because of serious 
limitations of the quality of the RCTs, imprecision and 
a high risk of publication bias. For electroacupuncture 
monotherapy in comparison with standard antidepres-
sants, low-quality evidence homogeneously suggested 
significant greater effects for severity and similar effects 
for remission. As an adjunctive treatment to antidepres-
sants, electroacupuncture effectiveness was supported 
by low quality of evidence showing a significant greater 
consistent and precise effect for depression severity. 
Although the mean adjunctive effect can be considered 
as large, the analysis based on only one RCT with overall 
low risk of bias and four RCTs of lower methodological 
quality that missed to include adjunctive sham acupunc-
ture. For remission rates, very low quality of evidence 
suggested no effects in adjunction to antidepressants. In 
addition, one RCT showed significant less AEs when elec-
troacupuncture was added to standard antidepressants.
Aromatherapy
The literature search revealed no meta-analysis on aroma-
therapy. A recent systematic review detected no RCTs in 
patients with a primary diagnosis of depression. However, 
two out of five of the reviewed studies on inhalation 
aromatherapy and five out of eight studies on aroma-
therapy massage have found significant antidepressive 
effects in mixed patient samples and healthy adults.116
Biofeedback
No meta-analysis on biofeedback was conducted to date. 
A recent systematic review revealed only one RCT on the 
defined inclusion criteria for depression showing some 
effects in contrast to sham psychotherapy.117
Herbs
St. John’s wort (Hypericum perforatum)
The effectiveness of St. John’s wort was meta-analysed 
by a Cochrane review of 29 RCTs150 and a more recent, 
higher quality meta-analysis of 35 RCTs.142 In comparison 
with placebo, St. John’s wort showed moderate quality 
evidence of significant greater reductions of depres-
sion severity (figure 2) and response rates (figure 4). 
The evidence had to be downgraded due to significant 
heterogeneity because of higher effects in studies from 
German-speaking countries than in those from the 
USA or other European countries. In contrast, very low 
quality of evidence suggested no superiority to placebo 
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Figure 5 Quality of evidence for depression relapse rates. ADM, antidepressant medication; I2, heterogeneity; MBCT, 
mindfulness-based cognitive therapy; n.c., not calculable because of only one included RCT; RR, risk ratio; TAU, treatment as 
usual.
comparison with standard antidepressants, St. John’s 
wort showed comparable severity reductions, response, 
remission, and relapse rates. The quality of the evidence 
of the meta-analyses of severity and relapse rates had to 
be downgraded to low and very low, respectively. The 
evidence of the response and remission rates was consid-
ered as moderate quality showing the same results in both 
German and studies from other countries but containing 
some RCTs with unclear risk of selection bias and detec-
tion bias. Moreover, both meta-analyses142 150 showed 
similar AEs of St. John’s wort to placebo but significant 
less AEs than standard antidepressants.
Saffron (Crocus sativus)
A moderate-quality meta-analysis examined the effec-
tiveness and safety of saffron on depression severity by 
including five RCTs in adult patients with major depres-
sion.147 It revealed very low quality of evidence for signif-
icant greater effects versus placebo and similar effects 
versus antidepressant medication up to 8 weeks of treat-
ment (figure 2). No serious AEs were reported, but 
patients receiving saffron tend to report more AEs than 
those receiving placebo and less AEs than those receiving 
antidepressant medication. Reasons for downgrading 
the evidence included no replication of the results (all 
included RCTs were conducted by the same research 
group), the small overall sample size and the possibly 
high risk of publication bias.
Curcumin (Curcuma longa)
For the intake of curcumin, a moderate-quality meta-anal-
ysis155 revealed very low quality of evidence suggesting a 
small but significant short-term effect of low heterogeneity 
on depression severity by pooling six RCTs (figure 2). No 
serious AEs were recorded. Evidence had to be down-
graded due to unclear risk of selection, performance, 
detection, attrition and reporting bias in over the half of 
the included RCTs, the imprecision of the pooled effect 
and the possibly high risk of publication bias.
Traditional Chinese herbs
A comprehensive but low-quality systematic review of 296 
RCTs of Chinese herbal medicine formulas and single herbs162 
revealed 21 RCTs of mostly unclear to high risk of selec-
tion, performance and detection bias and a serious risk 
of publication bias. Therefore, the evidence supporting 
the superiority above placebo and the similarity towards 
standard antidepressants regarding depression severity 
(figure 2) and response rates (figure 4) was assessed as 
very low.
Other herbs
For other than the described herbs, no meta-analyses 
were conducted to date. However, a systematic review109 
found three single RCTs that showed significant improve-
ment in depressive symptoms for Lavandula angustifolia 
as an adjunctive treatment to standard antidepressant 
drugs versus antidepressant drugs alone and for Echium 
amoenum and Rhodiola rosea versus placebo. No serious 
AEs were reported.
Homoeopathy
No meta-analysis on homoeopathic remedies for depression 
were conducted yet. A recent systematic review detected 
no placebo-controlled RCTs in patients with a primary 
diagnosis of depression.128
Hypnosis
No meta-analysis on hypnosis or self-hypnosis techniques 
met the inclusion criteria of this overview. The only avail-
able review on this topic126 included six RCTs among 
which only one RCT included adults with mild primary 
depression. Within the mixed sample of physically ill 
patients and healthy adults, (self-)hypnosis appeared to 
be effective in decreasing depressive symptoms.
Light therapy
A high-quality Cochrane review meta-analysed the effects 
of bright light therapy in adjunction to standard antide-
pressants versus sham light therapy plus antidepressants 
on severity and response rates in patients suffering from 
non-seasonal depression.161 By pooling 18 RCTs of overall 
unclear risk of bias, it revealed very low quality of evidence 
for a significant small but inconsistent and imprecise 
effect on depression severity (figure 2). A subgroup anal-
ysis of two RCTs with low risk of selection bias and detec-
tion bias revealed a significant large effect on depression 
severity but based on one non-peer-reviewed publica-
tion and one RCT that also included bipolar patients. 
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groups (figure 4). AEs were reported non-systematically 
but appeared to be comparable with sham light therapy 
except for hypomania that occurred more often under 
verum light therapy.161
For patients with seasonal patterns of depression, a 
meta-analysis of eight RCTs152 revealed very low quality of 
evidence for a significant medium effect on depression 
severity of light monotherapy in comparison with sham 
light therapy (figure 2). Risk of bias of individual RCTs, 
heterogeneity and safety were not analysed leading to an 
overall low quality of the meta-analysis and downgrading 
of the evidence.
Massage therapy
The literature search detected no meta-analysis of massage 
therapy in patients with a primary depression. However, 
massage therapy appeared to be effective in decreasing 
depressive symptoms in mixed samples of physically ill 
patients and healthy adults.132 Future research will show 




Short-term effects of improvisatory or structured dance 
therapy as a combination of movement-based work, inter-
active group components and insight/expressive methods 
were meta-analysed by a Cochrane review of high meth-
odological quality.153 It revealed a significant large pooled 
effect size for depression severity as an adjunctive treat-
ment option to standard medical/psychotherapeutic care 
based on two RCTs (figure 2). Although the meta-anal-
yses contained no heterogeneity and no imprecise CI, the 
evidence had to be downgraded to low quality because of 
mostly unclear/high risk of bias of one of the RCTs as well 
as the overall small sample size.
Chinese movement therapies
A low-quality meta-analysis on Chinese meditative move-
ment therapies revealed 30 RCTs, of which 2 RCTs on 
Qi Gong and 3 RCTs on Tai Chi met inclusion criteria for 
patients with mild to severe symptoms of primary depres-
sion.151 Very low quality of evidence suggested signifi-
cant short-term effects for Qi Gong but not for Tai Chi 
in comparison with TAU. The evidence had to be down-
graded due to very serious limitations of the quality of 
the RCTs and the meta-analysis, significant heterogeneity, 
imprecision and a possible high risk of publication bias.
Yoga
A high-quality meta-analysis of complex yoga interven-
tions for various depressive disorders found 12 RCTs,145 
of which 5 RCTs of mostly unclear risk of bias met the 
inclusion criteria of this overview. The pooled short-term 
effect on depression severity was of large size in compar-
ison with TAU and medium size in comparison with 
standard exercises (figure 2). However, the evidence was 
assessed as very low due to serious limitations of quality 
of the RCTs, significant heterogeneity, imprecision and a 
possible high risk of publication bias.
A further systematic review of yoga in major depres-
sive disorder, revealed five newer yoga RCTs but did not 
perform a meta-analysis because of high clinical hetero-
geneity. Risk of bias was comparably high and evidence 
mostly conflicting.106
Mindfulness-based interventions
Mindfulness-based cognitive therapy (MBCT)
A low-quality meta-analysis of mindfulness-based inter-
ventions in patients with major depression found four 
RCTs investigating the effects of MBCT and cognitive–
behavioural therapy (CBT) on depression severity.159 It 
revealed a significant large short-term effect of MBCT in 
comparison with TAU and similar effects in comparison 
with CBT (figure 2). However, the quality of the evidence 
was considered as very low due to the missing risk of bias 
assessment, inconsistency and imprecision.
A further moderate-quality systematic review on MBCT 
meta-analysed 9 RCTs on an individual patient data 
level.149 The sample consisted of patients with recurrent 
major depression currently in remission. After a period 
of 60 weeks, MBCT showed a significantly reduced risk of 
depressive relapse compared with those receiving antide-
pressant drugs (figure 5). No serious AEs were reported. 
The evidence was assessed as moderate due to a possible 
risk of publication bias.
Mindfulness-based stress reduction (MBSR)
RCTs of MBSR and MBSR-like interventions were 
meta-analysed by a recent review144 showing a significant 
large short-term effect on depression severity in compar-
ison with TAU and enhanced TAU (figure 2). The quality 
of evidence was assessed as low because of the overall 
unclear risk of selection and performance bias and signif-
icant heterogeneity.
Music therapy
Studies on active and receptive music therapy in older 
patients with a diagnosis of depression were summarised 
by a recent moderate-quality meta-analysis.163 Out of 
19 RCTs, 8 met the inclusion criteria for this overview. 
Pooled analyses of five of them revealed a significant 
medium effect size on depression severity against TAU 
up to 52 weeks, however with bigger short-term than 
long-term effects, considerable heterogeneity and overall 
unclear risk of selection, performance and detection bias 
resulting in very low quality of evidence. Further three 
RCTs of the same review revealed low-quality evidence for 
a significant large consistent and precise effect of music 
therapy as an adjunctive treatment to antidepressants 
(figure 2).
A newer Cochrane review139 found eight different RCTs 
showing a significant large pooled effect of music therapy 
on depression severity against TAU and similar effects 
as CBT (figure 2). However, both analyses revealed very 
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performance, detection and reporting bias, significant 
heterogeneity and imprecision.
Nutrition therapy
No meta-analyses on specific diets for patients with 
depression were published to date. A systematic review 
of 11 RCTs on whole-diet interventions in mostly healthy 
patients with subthreshold physical conditions revealed 
conflicting evidence on the effectiveness of those inter-
vention for the reduction of depressive symptoms.114
A further systematic review on fasting in patients with 
chronic pain and inflammatory diseases110 included one 
RCT and seven observational studies, which showed 
promising short-term but questionable longer term anti-
depressive effects.
Religious/spiritual interventions
Very low to low quality of evidence was found by a moder-
ate-quality systematic review of nine RCTs on Christian, 
Muslim and spiritual CBT adaptions.141 The analyses 
showed significant greater medium effects on depression 
severity against TAU and standard CBT (figure 2). Safety 
data were not reported.
Supplements
Inositol
A low-quality meta-analysis of two RCTs in patients with 
major depression154 revealed very low quality evidence 
for inositol as adjective to standard antidepressants versus 
placebo in combination to standard antidepressants 
(figure 2).
Magnesium
No meta-analysis of magnesium supplementation was 
found. A recent systematic review detected no RCTs in 
patients with a primary diagnosis of depression.107
Omega-3 fatty acids
A high-quality Cochrane review143 of 26 RCTs found 
conflicting evidence of the effectiveness of supplementa-
tion with omega-3 fatty acids versus placebo in patients 
with major depression as depression severity significantly 
improved while response and remission rates did not 
so (figures 2–4). One additional RCT with a very low 
sample size showed similar effects of omega-3 fatty acids 
on severity and response rates in comparison with antide-
pressant drug treatment (figures 2 and 4). However, all 
meta-analyses were based on very low quality of evidence 
because of limitations of the study quality, significant 
heterogeneity, imprecision and a possibly high risk of 
publication bias.
Probiotics
The effectiveness of the supplementation with probiotics 
on depression severity was analysed by a moderate-quality 
meta-analysis of five RCTs, of which only one RCT with 
overall low risk of bias was carried out on patients with 
major depression.148 The analysis of the RCT revealed 
a significant medium but imprecise short-term effect in 
comparison with placebo (figure 2). This led to overall very 
low quality of evidence for probiotics supplementation.
S-adenosyl methionine (SAMe)
A high-quality Cochrane review146 of the effectiveness and 
safety of SAMe supplementation on depression severity 
revealed two RCTs of low risk of bias that showed no 
significant pooled effects for SAMe monotherapy versus 
placebo. One RCT, also of low risk of bias, showed a signif-
icant medium short-term effect as adjunctive to standard 
antidepressant medication, both for depression severity. 
Further five RCTs, which were rated as having overall 
unclear risk of bias, showed similar pooled effects of SAMe 
monotherapy on depression severity compared with stan-
dard antidepressant medication (figure 2). Original RCTs 
reported safety issues insufficiently. For all meta-anal-
yses, the evidence was assessed as low to very low quality 
because of limitations of the study quality, heterogeneity, 
imprecision and a possibly high risk of publication bias.
Tryptophan
A moderate-quality Cochrane review found two RCTs 
investigating the effectiveness and safety of tryptophan 
supplementation on depression severity.158 Pooling the 
effects led to significant greater short-term response rates 
(figure 4) as well as significant more AEs in the trypto-
phan group than in the placebo group. The evidence 
was assessed as very low quality because of an unclear risk 
of detection, attrition and other bias, imprecision and a 
possible risk for publication bias.
Vitamins
For Vitamin B6, no meta-analysis was available. A system-
atic review without meta-analysis revealed two RCTs 
showing no significant effects when compared with 
placebo.119
Two further moderate to high-quality meta-analyses 
examined the effects of vitamin B9 (Folate) for major 
depressive patients. While a Cochrane review160 calcu-
lated a significant medium effect size of folate intake as 
an adjunctive intervention to standard drug treatment 
on depression severity, a more recent review140 revealed 
non-significant differences on severity and response rates 
(figures 2 and 3). In contrast, a long-term combined 
intake of Vitamin B6, B9 and B12 was found to be effective 
for relapse prevention after remission of symptoms as a 
result of one RCT (figure 5).140 However, all comparisons 
were based on very low quality of evidence mostly due to 
significant heterogeneity, imprecision and possible high 
risk of publication bias.
Another moderate-quality meta-analysis revealed 
evidence of the effectiveness of vitamin D intake on 
depression severity in comparison with placebo.157 The 
analysis of the two included RCTs revealed a significant 
medium short-term effect in favour of vitamin D in 
major depressed patients up to 8 weeks (figure 2). The 
quality of evidence was rated as very low due to limita-
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imprecision, a high risk of publication bias as well as 
insufficient reporting of AEs.
Zinc
The effectiveness of zinc for major depression was 
meta-analysed by a low-quality review of three RCTs.156 It 
revealed a significant pooled short-term effect of medium 
size and low heterogeneity when zinc was taken as an 
adjunctive to standard antidepressant drug treatment 
(figure 2). However, the available evidence had to be 
assessed as very low as the meta-analysis did not perform 
risk of bias assessments and did not report AEs.
dISCuSSIOn
This systematic review provided a comprehensive over-
view of the evidence of CAM treatments for patients with 
a diagnosis or clinical symptoms of depression. Moder-
ate-quality evidence suggested the efficacy, comparative 
effectiveness to standard antidepressants and safety of St. 
John’s wort on depression severity and response rates. For 
remission and relapse rates, the evidence was conflicting 
and of lower quality. Moreover, moderate quality evidence 
showed that MBCT was superior to standard antidepres-
sant drug treatment for the prevention of depression 
relapse in patients with recurrent major depression. 
Low-quality evidence suggested significant greater effects 
in favour of electroacupuncture in comparison with stan-
dard antidepressants alone and in adjunction to standard 
antidepressants for depression severity. For remission 
rates, low quality evidence revealed comparable effects 
of electroacupuncture and standard antidepressants. 
Further significant greater effects, which are based on 
low-quality evidence, were found for MBSR versus TAU, 
music therapy in adjunction to standard antidepressants, 
faith-adapted CBT versus CBT, and SAMe versus stan-
dard antidepressants. Other treatments such as manual 
acupuncture, aromatherapy, biofeedback, herbs (crocus 
sativus, curcuma longa, traditional Chinese herbs, lavan-
dula angustifolia, echium amoenum and rhodiola rosea), 
homoeopathy, hypnosis, bright light therapy, massage, 
meditative movement therapies (dance therapy, Qi Gong, 
Tai Chi and yoga), whole-diet interventions, fasting and 
supplementation with inositol, magnesium, omega-3 fatty 
acids, probiotics, tryptophan, B and D vitamins and zinc 
were based on very low quality of evidence or no level 1 
evidence.
The strengths of the review process included the 
comprehensive literature search based on a structured list 
of CAM specific topics, which had been operationalised 
for the Cochrane Collaboration.42 It therefore included 
evidence for more than the previously considered CAM 
approaches and provided systematic information where 
further high-quality studies are required. In addition, we 
only included results of RCTs of patients with a diagnosis 
of depression or clinical relevant depressive symptoms 
and excluded RCTs on samples with minor or secondary 
symptoms of depression by newly calculating effect sizes. 
Finally, we rated AMSTAR and considered the quality of 
the meta-analyses as well when grading the quality of the 
evidence.
The conclusions derived from this overview are limited 
due to possibly missing evidence from newer RCTs, which 
have not been summarised by the included systematic 
reviews and meta-analyses. As it was not within the scope 
of this overview, we did not separately search for indi-
vidual RCTs. We also did not include meta-analyses on 
studies of lower evidence levels, which may include bigger 
samples and may provide additional information about 
further possible treatment approaches. Moreover, we 
did not search online registries or conference proceed-
ings for unpublished or ongoing meta-analyses, which 
may limit the conclusions. Another reason that limits the 
quality of evidence consists in the unsatisfactory method-
ological quality of some of the included meta-analyses. 
Although the methodological quality of the original 
RCTs might be acceptable, the bad reporting of some 
meta-analyses led to downgraded evidence. In particular, 
meta-analyses often missed to search for grey literature, 
cite excluded studies, adequately assess risk of bias of the 
original studies and report complete I2 statistics. As the 
latter are known to be unstable in meta-analyses with a 
small numbers of studies,164 calculating confidence inter-
vals for I2 should be standard. Moreover, RCTs as well as 
meta-analyses often missed to systematically report on 
occurred AEs, which also limits the significance of the 
conclusions. In RCTs of non-pharmacological interven-
tions, there is always a high or unclear risk of performance 
bias and possibly high placebo effects. As such, adding 
credible sham interventions, controlling for patients’ 
expectances and performing of intention-to-treat anal-
yses is indispensable. However, meta-analyses mostly did 
not systematically assess these issues. In meta-analyses of 
pharmacological interventions, the influence of industrial 
funding sources was often not adequately analysed. Here, 
subgroup analyses of studies having received no funding/
non-industrial funding versus those having received 
industrial funding are needed. Results of meta-analyses 
that missed to report funding issues completely should 
interpreted with caution. In general, it should be noticed 
that all evidence is based on short-term pooled effects, 
except for meta-analyses of St. John’s wort, MBCT, music 
therapy and B and D vitamins that also provided longer 
term follow-up data.
Clinical recommendations for patients should follow 
the country-specific clinical practice guidelines consid-
ering the quality of evidence, the accessibility of the treat-
ment, costs and the preferences of the patients. While 
the guidelines agree31 32 34–36 165 166 that clinicians should 
select between either CBT or second-generation antide-
pressant drugs for the treatment of major depression, 
the restricted search strategy of some of the guidelines 
might limit their recommendations for CAM treatments. 
For patients who do reject or do not tolerate standard 
antidepressant drugs, one alternative treatment option 
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American Psychiatric Association Task Force report43 
and the CANMAT Depression Work Group33 as being 
proven sufficiently for the short-term by placebo-con-
trolled and equivalence trials with standard antidepres-
sants for mild to moderate major depression. Particularly 
for bridging the gap between diagnosis and getting access 
to psychotherapy and meanwhile reducing/not-wors-
ening depression severity, St. John’s wort may be consid-
ered as a possibly better tolerated alternative to standard 
antidepressant drugs.167 As St. John’s wort is accessible 
without prescription and currently not regulated by the 
US Food and Drug Administration, we agree with the 
ACP guidelines31 that it remains difficult for patients to 
obtain quality-controlled remedies. Moreover, St. John’s 
wort is associated with numerous herb-to-drug interac-
tions.168 Therefore, we would recommend clinicians to 
educate their patients about possible effects, side effects 
and interactions who in turn should not take St. John’s 
wort without professional advise.34 Despite those limita-
tions, we would not discourage a general therapeutic 
attempt with St. John’s wort, even if we disagree with the 
NICE guideline in this point.35 Clinicians may also inform 
patients with recurrent major depression currently in 
remission about the superiority of MBCT in comparison 
with standard antidepressants for relapse prevention.32–35 
Finally, patients should also be informed that many other 
CAM treatments might show promising effects but cannot 
be recommended until further higher quality studies will 
confirm their effectiveness and safety.
Further research is needed, particularly for interven-
tions that have shown preliminary evidence for reducing 
secondary symptoms of depression, promising short-term 
but no longer term effects or insufficient evidence due to 
low methodological quality of the original RCTs and/or 
the performed meta-analyses. Reporting of clinical trials 
and meta-analyses should necessarily follow the Consoli-
dated Standards of Reporting Trials (CONSORT)169 and 
PRISMA guidelines,37 respectively, including rigorous 
documentation and analysis of AEs. Especially Chinese 
and Indian trials are still found to be poorly reported and 
tended to present more positive conclusions than those 
from western countries.170 171 Moreover, seven of the 
included meta-analyses showed no more than poor meth-
odological quality. All were published in peer-reviewed 
journals in the past 5 years. One complementary journal 
is among them, while six of the journals are conventional 
psychiatric journals with impact factors ranging from 
2.419 to 4.369. Thus, particularly, the review process as 
well as the editorial work need to be improved. Further 
clinical practice guidelines should extend their search 
strategies and include standard search terms for CAM. 
This is also important for CAM therapies that do not show 
consistent evidence or that are not yet investigated. This 
information might be equally interesting for physicians as 
well as for patients to make an informed decision about 
the treatment for clinical depression.
COnCluSIOn
This overview of systematic reviews on CAM treatments 
for clinical depression aimed to provide a systematic 
search strategy and evidence base, on which further 
clinical practice guidelines may build their recommen-
dations. To improve quality of trials and meta-analyses, 
researchers, reviewers as well as editors are asked to 
ensure that future articles strictly adhere the CONSORT 
and PRISMA guidelines.
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